Expanded Bexxar Use
On the heels of Bexxar's complete transfer from Corixa to GSK comes this press release:
The BEXXAR Therapeutic Regimen is now indicated for the treatment of patients with CD-20 antigen expressing relapsed or refractory (nonresponsive), low-grade, follicular, or transformed non-Hodgkin's lymphoma, including patients with Rituxan (Rituximab) refractory non-Hodgkin's lymphoma. The original indication specified that patients have disease that was refractory to Rituxan and had relapsed following chemotherapy. Determination of the effectiveness of the BEXXAR Therapeutic Regimen was based on overall response rates in patients whose disease is refractory to chemotherapy alone or to chemotherapy and Rituxan.
So now patients who fall into the types of NHL that can be treated with Bexxar do not have to show that Rituxan has been tried and failed before trying Bexxar. Yahoo Press Release
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
